ORIC Pharmaceuticals, Inc. (ORIC) Cash Flow Statement

The OCF/NI ratio has been consistently below 1.0 in most quarters, with 2026Q2 at 0.76, meaning cash outflows are outpacing the accounting losses. This suggests that non-cash charges like SBC are not fully offsetting working capital outflows, and the gap may indicate deteriorating cash conversion efficiency. Investors should monitor whether this trend persists as clinical trials expand.

The FCF trajectory shows a steady escalation in cash consumption, with the most recent quarter's burn of $32.0M slightly above the prior year's level. This aligns with the income statement's rising R&D expenses, suggesting that increased investment in clinical programs is driving the cash outflow. Without revenue, the company remains entirely dependent on external financing to sustain operations.

The negligible capex suggests ORIC's business model relies on outsourced manufacturing and research, with no significant property, plant, or equipment requirements. This is typical for early-stage biotechs, but it also means that future growth will likely require substantial external capital for clinical trials rather than internal asset expansion. The low capital intensity does not mitigate the overall cash burn.

The erratic working capital adjustments, particularly the negative swings in 2025Q1 and 2024Q1, suggest timing differences in payments and receivables, though with no revenue, these are likely related to prepaid expenses and accrued liabilities. The cumulative negative impact indicates that working capital is a net user of cash, adding to the burn. This could reflect aggressive vendor payments or clinical trial prepayments, warranting closer scrutiny.

The absence of shareholder returns is consistent with a development-stage company conserving cash for research. The minor buyback in 2026Q2 is negligible and may be related to employee stock plans. This capital deployment strategy underscores the company's focus on advancing its pipeline, but it also means investors rely solely on clinical success for returns.

The cumulative OCF is less negative than net income, indicating that non-cash charges like SBC and D&A are partially offsetting the cash burn. However, this divergence is modest and does not signal earnings quality; rather, it reflects the growing SBC component, which is a non-cash expense. Investors should note that SBC, while non-cash, still dilutes shareholders and represents a real economic cost.